hair loss treatment CAS 872365-14-5 Fevipiprant

hair loss treatment CAS 872365-14-5 Fevipiprant

Min.Order / FOB Price:Get Latest Price

1 Gram	FOB Price: USD 5.0000

1 Gram

FOB Price: USD 5.0000

Min.Order :1 Gram
Purity: 99%
Payment Terms : L/C,D/A,D/P,T/T,Other

Keywords

Fevipiprant Fevipiprant powder anti hair loss

Quick Details

Appearance:powder
Application:anti hair loss
PackAge:Foil Bag, According to Client's Requirement
ProductionCapacity:1|Metric Ton|Day
Storage:store in cool and dry place
Transportation:FedEx DHL EMS or by Sea

Superiority:

1, High quality with competitive price:

1) Standard:BP/USP/EP/Enterprise standard

2) All Purity≥99%

3) We are manufacturer and can provide high quality products with factory price.

2, Fast and safe delivery

1) Parcel can be sent out in 24 hours after payment.Tracking number available

2) Secure and discreet shipment.Various transportation methods for your choice.

3) Customs pass rate ≥99%

4) We have our own agent/remailer/distributor who can help us ship our products very fast and safe,

and we have stock in there for transferring.

3,We have clients throughout the world.

1) Professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet their desire.

2) Market feedback and goods feedback will be appreciated, meeting customers's requirement is our responsibility.

14) High quality,competitive price,fast delivery ,first-class service gain the trust and praise from the customers.

Details:

Fevipiprant

Fevipiprant, also known as NVP-QAW039 or QAW039, is an oral active and potent CRTh2 receptor antagonist and potentially useful for asthma treatment. [(3)H]-QAW039 displayed high affinity for the human CRTh2 receptor (1.14 ± 0.44 nM) expressed in Chinese hamster ovary cells, the binding being reversible and competitive with the native agonist prostaglandin D2(PGD2). QAW039 was also a potent inhibitor of PGD2-induced cytokine release in human Th2 cells. Fevipiprant reduces eosinophilic airway inflammation and is well tolerated in patients with persistent moderate-to-severe asthma and raised sputum eosinophil counts despite inhaled corticosteroid treatment. Fevipiprant demonstrates a favorable safety profile.